Tissue compatibility of two biodegradable tubular scaffolds implanted adjacent to skin or buccal mucosa in mice

D. J. Aframian, R. S. Redman, Seiichi Yamano, J. Nikolovski, E. Cukierman, K. M. Yamada, M. F. Kriete, W. D. Swaim, D. J. Mooney, Bruce J. Baum

Research output: Contribution to journalArticle

Abstract

Radiation therapy for cancer in the head and neck region leads to a marked loss of salivary gland parenchyma, resulting in a severe reduction of salivary secretions. Currently, there is no satisfactory treatment for these patients. To address this problem, we are using both tissue engineering and gene transfer principles to develop an orally implantable, artificial fluid-secreting device. In the present study, we examined the tissue compatibility of two biodegradable substrata potentially useful in fabricating such a device. We implanted in Balb/c mice tubular scaffolds of poly-L-lactic acid (PLLA), poly-glycolic acid coated with PLLA (PGA/PLLA), or nothing (sham-operated controls) either beneath the skin on the back, a site widely used in earlier toxicity and biocompatibility studies, or adjacent to the buccal mucosa, a site quite different functionally and immunologically. At 1, 3, 7, 14, and 28 days postimplantation, implant sites were examined histologically, and systemic responses were assessed by conventional clinical chemistry and hematology analyses. Inflammatory responses in the connective tissue were similar regardless of site or type of polymer implant used. However, inflammatory reactions were shorter and without epithelioid and giant cells in sham-operated controls. Also, biodegradation proceeded more slowly with the PLLA tubules than with the PGA/PLLA tubules. No significant changes in clinical chemistry and hematology were seen due to the implantation of tubular scaffolds. These results indicate that the tissue responses to PLLA and PGA/PLLA scaffolds are generally similar in areas subjacent to skin in the back and oral cavity. However, these studies also identified several potentially significant concerns that must be addressed prior to initiating any clinical applications of this device.

Original languageEnglish (US)
Pages (from-to)649-659
Number of pages11
JournalTissue Engineering
Volume8
Issue number4
DOIs
StatePublished - 2002

Fingerprint

glycolic acid
Histocompatibility
Mouth Mucosa
Lactic acid
Scaffolds (biology)
Skin
Tissue
Clinical Chemistry
Hematology
Scaffolds
Equipment and Supplies
Acids
Gene transfer
Epithelioid Cells
Radiotherapy
Giant Cells
Tissue Engineering
Head and Neck Neoplasms
Biodegradation
Salivary Glands

ASJC Scopus subject areas

  • Biophysics
  • Cell Biology
  • Biotechnology

Cite this

Tissue compatibility of two biodegradable tubular scaffolds implanted adjacent to skin or buccal mucosa in mice. / Aframian, D. J.; Redman, R. S.; Yamano, Seiichi; Nikolovski, J.; Cukierman, E.; Yamada, K. M.; Kriete, M. F.; Swaim, W. D.; Mooney, D. J.; Baum, Bruce J.

In: Tissue Engineering, Vol. 8, No. 4, 2002, p. 649-659.

Research output: Contribution to journalArticle

Aframian, DJ, Redman, RS, Yamano, S, Nikolovski, J, Cukierman, E, Yamada, KM, Kriete, MF, Swaim, WD, Mooney, DJ & Baum, BJ 2002, 'Tissue compatibility of two biodegradable tubular scaffolds implanted adjacent to skin or buccal mucosa in mice', Tissue Engineering, vol. 8, no. 4, pp. 649-659. https://doi.org/10.1089/107632702760240562
Aframian, D. J. ; Redman, R. S. ; Yamano, Seiichi ; Nikolovski, J. ; Cukierman, E. ; Yamada, K. M. ; Kriete, M. F. ; Swaim, W. D. ; Mooney, D. J. ; Baum, Bruce J. / Tissue compatibility of two biodegradable tubular scaffolds implanted adjacent to skin or buccal mucosa in mice. In: Tissue Engineering. 2002 ; Vol. 8, No. 4. pp. 649-659.
@article{b939820e470247538c2d4ba961a2c290,
title = "Tissue compatibility of two biodegradable tubular scaffolds implanted adjacent to skin or buccal mucosa in mice",
abstract = "Radiation therapy for cancer in the head and neck region leads to a marked loss of salivary gland parenchyma, resulting in a severe reduction of salivary secretions. Currently, there is no satisfactory treatment for these patients. To address this problem, we are using both tissue engineering and gene transfer principles to develop an orally implantable, artificial fluid-secreting device. In the present study, we examined the tissue compatibility of two biodegradable substrata potentially useful in fabricating such a device. We implanted in Balb/c mice tubular scaffolds of poly-L-lactic acid (PLLA), poly-glycolic acid coated with PLLA (PGA/PLLA), or nothing (sham-operated controls) either beneath the skin on the back, a site widely used in earlier toxicity and biocompatibility studies, or adjacent to the buccal mucosa, a site quite different functionally and immunologically. At 1, 3, 7, 14, and 28 days postimplantation, implant sites were examined histologically, and systemic responses were assessed by conventional clinical chemistry and hematology analyses. Inflammatory responses in the connective tissue were similar regardless of site or type of polymer implant used. However, inflammatory reactions were shorter and without epithelioid and giant cells in sham-operated controls. Also, biodegradation proceeded more slowly with the PLLA tubules than with the PGA/PLLA tubules. No significant changes in clinical chemistry and hematology were seen due to the implantation of tubular scaffolds. These results indicate that the tissue responses to PLLA and PGA/PLLA scaffolds are generally similar in areas subjacent to skin in the back and oral cavity. However, these studies also identified several potentially significant concerns that must be addressed prior to initiating any clinical applications of this device.",
author = "Aframian, {D. J.} and Redman, {R. S.} and Seiichi Yamano and J. Nikolovski and E. Cukierman and Yamada, {K. M.} and Kriete, {M. F.} and Swaim, {W. D.} and Mooney, {D. J.} and Baum, {Bruce J.}",
year = "2002",
doi = "10.1089/107632702760240562",
language = "English (US)",
volume = "8",
pages = "649--659",
journal = "Tissue Engineering",
issn = "1076-3279",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Tissue compatibility of two biodegradable tubular scaffolds implanted adjacent to skin or buccal mucosa in mice

AU - Aframian, D. J.

AU - Redman, R. S.

AU - Yamano, Seiichi

AU - Nikolovski, J.

AU - Cukierman, E.

AU - Yamada, K. M.

AU - Kriete, M. F.

AU - Swaim, W. D.

AU - Mooney, D. J.

AU - Baum, Bruce J.

PY - 2002

Y1 - 2002

N2 - Radiation therapy for cancer in the head and neck region leads to a marked loss of salivary gland parenchyma, resulting in a severe reduction of salivary secretions. Currently, there is no satisfactory treatment for these patients. To address this problem, we are using both tissue engineering and gene transfer principles to develop an orally implantable, artificial fluid-secreting device. In the present study, we examined the tissue compatibility of two biodegradable substrata potentially useful in fabricating such a device. We implanted in Balb/c mice tubular scaffolds of poly-L-lactic acid (PLLA), poly-glycolic acid coated with PLLA (PGA/PLLA), or nothing (sham-operated controls) either beneath the skin on the back, a site widely used in earlier toxicity and biocompatibility studies, or adjacent to the buccal mucosa, a site quite different functionally and immunologically. At 1, 3, 7, 14, and 28 days postimplantation, implant sites were examined histologically, and systemic responses were assessed by conventional clinical chemistry and hematology analyses. Inflammatory responses in the connective tissue were similar regardless of site or type of polymer implant used. However, inflammatory reactions were shorter and without epithelioid and giant cells in sham-operated controls. Also, biodegradation proceeded more slowly with the PLLA tubules than with the PGA/PLLA tubules. No significant changes in clinical chemistry and hematology were seen due to the implantation of tubular scaffolds. These results indicate that the tissue responses to PLLA and PGA/PLLA scaffolds are generally similar in areas subjacent to skin in the back and oral cavity. However, these studies also identified several potentially significant concerns that must be addressed prior to initiating any clinical applications of this device.

AB - Radiation therapy for cancer in the head and neck region leads to a marked loss of salivary gland parenchyma, resulting in a severe reduction of salivary secretions. Currently, there is no satisfactory treatment for these patients. To address this problem, we are using both tissue engineering and gene transfer principles to develop an orally implantable, artificial fluid-secreting device. In the present study, we examined the tissue compatibility of two biodegradable substrata potentially useful in fabricating such a device. We implanted in Balb/c mice tubular scaffolds of poly-L-lactic acid (PLLA), poly-glycolic acid coated with PLLA (PGA/PLLA), or nothing (sham-operated controls) either beneath the skin on the back, a site widely used in earlier toxicity and biocompatibility studies, or adjacent to the buccal mucosa, a site quite different functionally and immunologically. At 1, 3, 7, 14, and 28 days postimplantation, implant sites were examined histologically, and systemic responses were assessed by conventional clinical chemistry and hematology analyses. Inflammatory responses in the connective tissue were similar regardless of site or type of polymer implant used. However, inflammatory reactions were shorter and without epithelioid and giant cells in sham-operated controls. Also, biodegradation proceeded more slowly with the PLLA tubules than with the PGA/PLLA tubules. No significant changes in clinical chemistry and hematology were seen due to the implantation of tubular scaffolds. These results indicate that the tissue responses to PLLA and PGA/PLLA scaffolds are generally similar in areas subjacent to skin in the back and oral cavity. However, these studies also identified several potentially significant concerns that must be addressed prior to initiating any clinical applications of this device.

UR - http://www.scopus.com/inward/record.url?scp=0035988724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035988724&partnerID=8YFLogxK

U2 - 10.1089/107632702760240562

DO - 10.1089/107632702760240562

M3 - Article

C2 - 12202004

AN - SCOPUS:0035988724

VL - 8

SP - 649

EP - 659

JO - Tissue Engineering

JF - Tissue Engineering

SN - 1076-3279

IS - 4

ER -